Targeting the untargetable KRAS in cancer therapy

RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in approximately 30% of all human cancers. As the most frequently mutated RAS isoform, KRAS is intensively studied in the past years. Despite its well-recognized importance in cancer malignancy, continuous effort...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pingyu, Wang, Yijun, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804475/
https://www.ncbi.nlm.nih.gov/pubmed/31649840
http://dx.doi.org/10.1016/j.apsb.2019.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804475/
https://www.ncbi.nlm.nih.gov/pubmed/31649840
http://dx.doi.org/10.1016/j.apsb.2019.03.002

Ejemplares similares